专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021222168A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF TDP-43 PROTEINOPATHIES 审中-公开
公开(公告)号：WO2021222168A2
公开(公告)日：2021-11-04
申请号：PCT/US2021/029289
申请日：2021-04-27
申请人： SOLA BIOSCIENCES LLC
发明人： HISHIYA, Akinori , KOYA, Keizo
IPC分类号： C07K14/47 , C12N15/86 , C07K16/18 , A01K2227/105 , A01K2267/0318 , A61K48/005 , A61P21/00 , A61P25/28 , C07K14/4702 , C07K2317/622 , C07K2319/01 , C07K2319/35 , C12N2750/14143
摘要： A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically reduce TDP-43-mediated protein aggregation and associated proteopathies is disclosed.

2. 发明申请

WO2023060221A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEOPATHIES 审中-公开
公开(公告)号：WO2023060221A2
公开(公告)日：2023-04-13
申请号：PCT/US2022/077739
申请日：2022-10-07
申请人： SOLA BIOSCIENCES LLC
发明人： HISHIYA, Akinori , KOYA, Keizo
IPC分类号： C07K14/47 , C07K14/575 , C07K14/74 , C07K14/81 , C07K14/4711 , C07K14/4712 , C07K14/70539 , C07K14/8125 , C07K2319/03
摘要： A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically reduce the aggregation or misfolding of, or restore the function of a target protein, is disclosed.

3. 发明申请

WO2022093736A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
公开(公告)号：WO2022093736A1
公开(公告)日：2022-05-05
申请号：PCT/US2021/056539
申请日：2021-10-26
申请人： SOLA BIOSCIENCES LLC
发明人： HISHIYA, Akinori , KOYA, Keizo
IPC分类号： C07K14/47
摘要： A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically reduce tau-mediated protein aggregation and associated proteopathies is disclosed.

4. 发明申请

WO2021248038A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES 审中-公开
公开(公告)号：WO2021248038A1
公开(公告)日：2021-12-09
申请号：PCT/US2021/035958
申请日：2021-06-04
申请人： SOLA BIOSCIENCES LLC
发明人： HISHIYA, Akinori , KOYA, Keizo
IPC分类号： C07K14/47 , A61P25/28 , A61P25/16 , C07K2319/35
摘要： A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically reduce α-synuclein-mediated protein aggregation and associated proteopathies is disclosed.

5. 发明申请

WO2021207636A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS 审中-公开
公开(公告)号：WO2021207636A2
公开(公告)日：2021-10-14
申请号：PCT/US2021/026633
申请日：2021-04-09
申请人： SOLA BIOSCIENCES LLC
发明人： HISHIYA, Akinori , KOYA, Keizo
IPC分类号： C07K14/47 , C07K2319/00 , C07K2319/70
摘要： A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically reduce polyglutamine-mediated protein aggregation is disclosed.

6. 发明申请

WO2018058088A1 CELL-ASSOCIATED SECRETION-ENHANCING FUSION PROTEINS 审中-公开
标题翻译：细胞相关分泌增强融合蛋白
公开(公告)号：WO2018058088A1
公开(公告)日：2018-03-29
申请号：PCT/US2017/053383
申请日：2017-09-26
申请人： SOLA BIOSCIENCES, LLC
发明人： HISHIYA, Akinori
IPC分类号： C07K16/00 , C07K16/24 , C07K14/47
摘要： Cell-associated secretion-enhancing fusion proteins are disclosed that comprise a target protein binding domain and a transmembrane retention domain. Co-expression in a host cell of a fusion protein and a target protein of interest that is temporarily bound by the fusion protein leads to an increased level of target protein secreted from the host cell. The fusion proteins are engineered to be retained with the producing host cell, thus eliminating a non-natural component from the extracellular media of the host cell and simplifying purification of the target protein. Nucleic acid molecules encoding such fusion proteins are also disclosed for use in expressing the fusion proteins in host cells, for use in restoring lost or diminished cell functions, and for use in treating diseases characterized by a lost or diminished cell function. Methods and compositions comprising fusion proteins of the invention are disclosed for use in enhancing the level of co-expressed target proteins secreted from host cells.
摘要翻译：公开了包含靶蛋白结合结构域和跨膜保留结构域的细胞相关分泌增强融合蛋白。在宿主细胞中融合蛋白和暂时与融合蛋白结合的感兴趣靶蛋白的共表达导致宿主细胞分泌的靶蛋白水平增加。将融合蛋白改造成与产生宿主细胞一起保留，从而从宿主细胞的细胞外培养基中消除非天然组分并简化靶蛋白的纯化。还公开了编码这种融合蛋白的核酸分子用于在宿主细胞中表达融合蛋白，用于恢复丢失或减少的细胞功能，并用于治疗以细胞功能丧失或减弱为特征的疾病。公开了包含本发明融合蛋白的方法和组合物用于增强从宿主细胞分泌的共表达的靶蛋白的水平。

7. 发明申请

WO2023060248A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF P53-MEDIATED CANCERS 审中-公开
公开(公告)号：WO2023060248A1
公开(公告)日：2023-04-13
申请号：PCT/US2022/077779
申请日：2022-10-07
申请人： SOLA BIOSCIENCES LLC
发明人： HISHIYA, Akinori , KOYA, Keizo
IPC分类号： C07K14/47 , A61P35/00 , A61K38/00 , C07K19/00 , C07K2319/00
摘要： A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically restore p53-function is disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式